Scalper1 News
With the launch of Alprolix in May and Eloctate coming in July, Biogen Idec is on the leading edge of the first new class of hemophilia treatments to come along in 15 years. The question is, how interested are justifiably cautious patients in trying new things? Although hemophilia is fairly well-known due to its presence in some of Europe’s royal families, the disease is actually rare. Novo Nordisk (NVO) estimates that there are fewer than 500,000 Scalper1 News
Scalper1 News